Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Laboratories (CLB) Cash from Financing Activities (2022 - 2025)

Core Laboratories (CLB) has 4 years of Cash from Financing Activities data on record, last reported at -$16.5 million in Q3 2025.

  • For Q3 2025, Cash from Financing Activities fell 86.41% year-over-year to -$16.5 million; the TTM value through Sep 2025 reached -$43.5 million, up 3.45%, while the annual FY2024 figure was -$46.0 million, 149.16% down from the prior year.
  • Cash from Financing Activities reached -$16.5 million in Q3 2025 per CLB's latest filing, down from -$3.2 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $6.1 million in Q1 2023 and bottomed at -$19.4 million in Q4 2024.
  • Average Cash from Financing Activities over 4 years is -$8.2 million, with a median of -$6.0 million recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: crashed 32464.29% in 2024, then soared 76.62% in 2025.
  • A 4-year view of Cash from Financing Activities shows it stood at -$12.6 million in 2022, then tumbled by 46.97% to -$18.5 million in 2023, then fell by 4.84% to -$19.4 million in 2024, then grew by 15.07% to -$16.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were -$16.5 million in Q3 2025, -$3.2 million in Q2 2025, and -$4.5 million in Q1 2025.